Latest news
Trump's 2028 Generic Drug Tariff Plan Puts U.S. Onshoring Ambitions to a Two-Year Test - Quarterly Profit Report - dars.gov.etdars.gov.et · Sun, 02 Aug 2026 10:57:20 GMTTrump's 2028 Generic Drug Tariff Plan Puts U.S. Onshoring Ambitions to a Two-Year Test - Annual Financial Report - dars.gov.etdars.gov.et · Sun, 02 Aug 2026 10:57:20 GMTTrump’s Generic Drug Tariffs Set for 2028: Two-Year Delay Puts U.S. Onshoring Ambitions to the Test - EPS Miss Report - dars.gov.etdars.gov.et · Sun, 02 Aug 2026 10:16:48 GMTTrump to Impose Generic Drug Tariffs Starting 2028, Testing U.S. Onshoring Ambitions - Profit Margin Analysis - dars.gov.etdars.gov.et · Sun, 02 Aug 2026 03:11:10 GMTTrump's 2028 Generic Drug Tariff Plan Puts U.S. Onshoring Ambitions to the Test - Core Business Growth - dars.gov.etdars.gov.et · Sun, 02 Aug 2026 01:16:06 GMTTrump's Generic Drug Tariff Plan Slated for 2028 Tests U.S. Onshoring Ambitions - Earnings Turnaround - dars.gov.etdars.gov.et · Sun, 02 Aug 2026 00:26:09 GMTTrump Targets Generic Drug Tariffs by 2028, Two-Year Delay Puts U.S. Onshoring Ambitions to the Test - Financial Health Score - dars.gov.etdars.gov.et · Sat, 01 Aug 2026 16:51:51 GMTTrump Targets Generic Drug Tariffs by 2028, Two-Year Delay Puts U.S. Onshoring Ambitions to the Test - Guidance Accuracy Score - dars.gov.etdars.gov.et · Sat, 01 Aug 2026 16:51:51 GMT